Natera, Inc. (NASDAQ:NTRA) Insider Sells $296,082.00 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Jonathan Sheena sold 2,700 shares of the company’s stock in a transaction that occurred on Tuesday, June 18th. The shares were sold at an average price of $109.66, for a total value of $296,082.00. Following the transaction, the insider now directly owns 304,508 shares in the company, valued at approximately $33,392,347.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jonathan Sheena also recently made the following trade(s):

• On Thursday, May 23rd, Jonathan Sheena sold 1,000 shares of Natera stock. The stock was sold at an average price of $108.30, for a total transaction of $108,300.00.
• On Thursday, April 25th, Jonathan Sheena sold 1,000 shares of Natera stock. The shares were sold at an average price of $89.55, for a total transaction of $89,550.00.
• On Wednesday, April 3rd, Jonathan Sheena sold 26,700 shares of Natera stock. The shares were sold at an average price of $92.47, for a total value of $2,468,949.00.
• On Thursday, March 28th, Jonathan Sheena sold 447 shares of Natera stock. The shares were sold at an average price of $90.22, for a total transaction of $40,328.34.

Natera Stock Down 0.1 %

NASDAQ:NTRA opened at $107.11 on Monday. The company has a debt-to-equity ratio of 0.36, a quick ratio of 3.98 and a current ratio of 4.12. Natera, Inc. has a 52 week low of $36.90 and a 52 week high of $117.23. The stock’s 50-day moving average price is $102.42 and its 200-day moving average price is $84.19.

Natera (NASDAQ:NTRA) last announced its earnings results on Thursday, May 9th. The medical research company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.16. Natera had a negative return on equity of 49.72% and a negative net margin of 30.24%. The business had revenue of $367.70 million during the quarter, compared to the consensus estimate of $316.31 million. During the same period in the prior year, the company posted ($1.23) EPS. The business’s quarterly revenue was up 52.1% on a year-over-year basis. Sell-side analysts predict that Natera, Inc. will post -2.43 EPS for the current year.

Institutional Trading of Natera

Institutional investors have recently modified their holdings of the stock. RiverPark Advisors LLC acquired a new position in shares of Natera during the 4th quarter worth about $27,000. Principal Securities Inc. purchased a new stake in shares of Natera during the fourth quarter worth approximately $32,000. YHB Investment Advisors Inc. purchased a new position in Natera in the 1st quarter valued at $36,000. Oliver Lagore Vanvalin Investment Group boosted its stake in Natera by 109.3% during the 4th quarter. Oliver Lagore Vanvalin Investment Group now owns 745 shares of the medical research company’s stock worth $47,000 after purchasing an additional 389 shares during the last quarter. Finally, Arcadia Investment Management Corp MI boosted its stake in Natera by 47.8% during the 1st quarter. Arcadia Investment Management Corp MI now owns 538 shares of the medical research company’s stock worth $49,000 after purchasing an additional 174 shares during the last quarter. Institutional investors and hedge funds own 99.90% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on NTRA. Sanford C. Bernstein raised Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target for the company in a research report on Friday, April 5th. Robert W. Baird lifted their price objective on shares of Natera from $99.00 to $117.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Craig Hallum began coverage on Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 price target on the stock. StockNews.com raised Natera from a “sell” rating to a “hold” rating in a research report on Friday, May 17th. Finally, The Goldman Sachs Group boosted their target price on Natera from $90.00 to $100.00 and gave the stock a “buy” rating in a research note on Monday, April 15th. One research analyst has rated the stock with a hold rating and sixteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $101.19.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.